Jan 9 (Reuters) – Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Eikon Therapeutics is a late-stage clinical biopharmaceutical firm developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.
It will list on the Nasdaq under the symbol “EIKN”.
J.P. Morgan, Morgan Stanley and BofA Securities are the underwriters for the offering.
(Reporting by Prakhar Srivastava in Bengaluru; Editing by Alan Barona)
